Abstract:Docetaxel (DTX) is classified as a class IV drug that exhibits poor aqueous solubility (6–7 μg/mL in water) and permeability (P-glycoprotein substrate). The main objective of this study was to construct, characterize, and evaluate docetaxel loaded nanomicellar formulation in vitro for oral delivery to enhance the absorption and bioavailability of DTX, as well as to circumvent P-gp efflux inhibition. Formulations were prepared with two polymeric surfactants, hydrogenated castor oil-40 (HCO-40) and D-α-Tocopherol polyethylene glycol 1000 succinate (VIT E TPGS) with solvent evaporation technique, and the resulting DTX nanomicellar formulations were characterized by proton nuclear magnetic resonance spectroscopy (1H NMR), Fourier Transform Infrared Spectroscopy (FT–IR), X-ray powder diffraction (XRD), and transmission electron microscopy (TEM). Proton NMR, FT–IR, and XRD data indicated that DTX was completely encapsulated within the hydrophobic core of the nanomicelles in its amorphous state. TEM data revealed a smooth spherical shape of the nanomicellar formulation. The optimized formulation (F-2) possessed a mean diameter of 13.42 nm, a zeta potential of −0.19 mV, with a 99.3% entrapment efficiency. Dilution stability study indicated that nanomicelles were stable up to 100-fold dilution with minimal change in size, poly dispersity index (PDI), and zeta potential. In vitro cytotoxicity study revealed higher anticancer activity of DTX nanomicelles at 5 μM compared to the native drug against breast cancer cell line (MCF-7) cells. The LC–MS data confirmed the chemical stability of DTX within the nanomicelles. In vitro drug release study demonstrated faster dissolution of DTX from the nanomicelles compared to the naked drug. Our experimental results exhibit that nanomicelles could be a drug delivery system of choice to encapsulate drugs with low aqueous solubility and permeability that can preserve the stability of the active constituents to provide anticancer activity.

Advances in nano-drug delivery systems for docetaxel

How Nanotechnology Can Enhance Docetaxel Therapy

Current Development in Nanoformulations of Docetaxel

Current development in nanoformulations of docetaxel.

Advances in the formulations of non-injection administration of docetaxel.

Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel.

Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview

Recent progress in nanoformulations of cabazitaxel

Progress of Clinical Research on New Nano-Drug Delivery System of Paclitaxel

Self-Delivering Prodrug-Nanoassemblies Fabricated by Disulfide Bond Bridged Oleate Prodrug of Docetaxel for Breast Cancer Therapy

Emerging nanotaxanes for cancer therapy

Research progress of paclitaxel drug delivery systems

Synthesis of Calcium Phosphate Nanoparticle‐Based Docetaxel Delivery System and Its in Vitro Anticancer Activity

Recent Progress of Paclitaxel Delivery Systems: Covalent and Noncovalent Approaches

Self-Assembled Nanomicellar Formulation of Docetaxel as a Potential Breast Cancer Chemotherapeutic System

Preclinical evaluation of albumin-bound docetaxel nanoparticles as potential anti-cancer products

Nitric oxide-releasing docetaxel prodrug nanoplatforms for effective cancer therapy

Intelligent polymeric micelles: development and application as drug delivery for docetaxel

Anti-Cancer Activity Based on the High Docetaxel Loaded Poly(2-Oxazoline)s Micelles

Enhanced Tolerance and Antitumor Efficacy by Docetaxel-Loaded Albumin Nanoparticles

Advanced Nano-Carriers For Anti-Tumor Drug Loading